Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Norah G Verbout, PhD, Christina U Lorentz, PhD, Brandon D Markway, PhD, Joseph J Shatzel, MD, Erik I Tucker, PhD, Andras Gruber, MD

Blood (2019) 134 (Supplement_1): 2433.

https://doi.org/10.1182/blood-2019-124999

Published: 2019

Journal Articles

MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis

Pieter Sonneveld, MDPhD, Katja C. Weisel, Yan Li, Elisabeth Kueenburg, Shona Collins, Antonia Di Micco, Barbara Rosettani, Pamela Bacon, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 1847.

https://doi.org/10.1182/blood.V130.Suppl_1.1847.1847

Published: 2017

Journal Articles

Pharmacokinetics and Pharmacodynamics of Ionis-FXI Rx , an Antisense Inhibitor of Factor XI, in Patients with End-Stage Renal Disease on Hemodialysis

Claudette Bethune, PhD, Michael Walsh, MD, PhD, Bill Jung, PhD, Rosie Yu, PhD, Richard S Geary, PhD, Sanjay Bhanot, MD PhD

Blood (2017) 130 (Supplement 1): 1116.

https://doi.org/10.1182/blood.V130.Suppl_1.1116.1116

Published: 2017

Journal Articles

Treatment of Myeloma Cast Nephropathy (MCN): A Randomized Trial Comparing Intensive Haemodialysis (HD) with High Cut-Off (HCO) or Standard High-Flux Dialyzer in Patients Receiving a Bortezomib-Based Regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT))

Frank Bridoux, MD PhD, Brigitte Pegourie, MD, Karine Augeul-Meunier, MD, Bruno Royer, MD, Bertrand Joly, MD, Thierry Lamy, MD PhD, Brigitte Kolb, Lofti Benboubker, Bertrand Arnulf, MD, Arnaud Jaccard, MD PhD, Sylvie Chevret, Jean-Paul Fermand, MD

Blood (2016) 128 (22): 978.

https://doi.org/10.1182/blood.V128.22.978.978

Published: 2016

Journal Articles

Dabigatran Pharmacokinetics and Pharmacodynamics during Renal Replacement Therapy

Alison Martin, MD, Rommel Tirona, PhD, Moist Louise, MD FRCP, Alejandro Lazo-Langner, MD MSc

Blood (2015) 126 (23): 4734.

https://doi.org/10.1182/blood.V126.23.4734.4734

Published: 2015

Journal Articles

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Neeraj Gupta, PhD, Michael J Hanley, PhD, R. Donald Harvey, PharmD, Ashraf Z Badros, MD, Brea C. Lipe, MD, Vishal Kukreti, Jesus G. Berdeja, MD, Huyuan Yang, PhD, Ai-Min Hui, MD PhD, Xiaoquan Zhang, MD PhD, Karthik Venkatakrishnan, PhD, Ajai Chari, MD

Blood (2015) 126 (23): 4227.

https://doi.org/10.1182/blood.V126.23.4227.4227

Published: 2015

Journal Articles

An International Study of High Cut-off Hemodialysis for the Management of Myeloma Kidney,

Colin A Hutchison, MB, CHB, Anne Bevins, BMedSc, Graham Mead, PhD, Mark Cook

Blood (2011) 118 (21): 3974.

https://doi.org/10.1182/blood.V118.21.3974.3974

Published: 2011

Journal Articles

A Tertiary Care University Hospital Thrombosis Consultation Service: Patient Volume and Characteristics, Requesting Service and Reason for Consult

Rufaro S. Chitsike, MD, Mark Blostein, Vicky Tagalakis, MD, MSc, Andrew Hirsch, April Shamy, MD, FRCP(C), Chantal Cassis, MD, Vicky Springmann, Susan R. Kahn, MD, MSc

Blood (2011) 118 (21): 4751.

https://doi.org/10.1182/blood.V118.21.4751.4751

Published: 2011

Journal Articles

A Review of Multiple Myeloma Patients on Dialysis Treated with High Cutoff Hemodialysis

Tiina Podymow, MD, Ahsan Alam, MD, Murray Vasilevsky, MD, Roch Beauchemin, RN, Chaim Shustik, MD, Michael Sebag, MD, PhD

Blood (2010) 116 (21): 5002.

https://doi.org/10.1182/blood.V116.21.5002.5002

Published: 2010

Journal Articles

Upregulation of Myeloperoxidase in End Stage Renal Disease and Its Modulation by Hemodialysis. A Paradoxical Paradigm.

Josephine Cunanan, MD, Debra Hoppensteadt, PhD, Vinod Bansal, MD, Jawed Fareed, PhD

Blood (2006) 108 (11): 3838.

https://doi.org/10.1182/blood.V108.11.3838.3838

Published: 2006

Journal Articles

Rapid Removal of Free Light Chains from Serum by Hemodialysis for Patients with Myeloma Kidney.

Arthur R. Bradwell, MB, ChB, FRCP, Neil D. Evans, PhD, Mike J. Chappell, PhD, Paul Cockwell, FRCP, Steven D. Reid, PhD, John Harrison, Colin Hutchison, MRCP, Graham P. Mead, PhD

Blood (2005) 106 (11): 3482.

https://doi.org/10.1182/blood.V106.11.3482.3482

Published: 2005

NARROW

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis

Pharmacokinetics and Pharmacodynamics of Ionis-FXI Rx , an Antisense Inhibitor of Factor XI, in Patients with End-Stage Renal Disease on Hemodialysis

Dabigatran Pharmacokinetics and Pharmacodynamics during Renal Replacement Therapy

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

An International Study of High Cut-off Hemodialysis for the Management of Myeloma Kidney,

A Tertiary Care University Hospital Thrombosis Consultation Service: Patient Volume and Characteristics, Requesting Service and Reason for Consult

A Review of Multiple Myeloma Patients on Dialysis Treated with High Cutoff Hemodialysis

Upregulation of Myeloperoxidase in End Stage Renal Disease and Its Modulation by Hemodialysis. A Paradoxical Paradigm.

Rapid Removal of Free Light Chains from Serum by Hemodialysis for Patients with Myeloma Kidney.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only